Related Experiment Videos
Vaccines for colorectal cancer
H J Zeh1, K Stavely-O'Carroll, M A Choti
1Division of Surgical Oncology Dept of Surgery, The Johns Hopkins Hospital, 600 N. Wolfe Street, Halsted 614, Baltimore, MD, USA.
Trends in Molecular Medicine
|June 27, 2001
Summary
Despite advances, advanced colorectal cancer survival is poor. Immunotherapy, leveraging the immune system
Area of Science:
- Oncology and Immunology
- Cancer immunotherapy research
- Colorectal cancer (CRC) treatment
Background:
- Advanced locoregional colorectal cancer (CRC) survival remains below 50% despite current treatments.
- Adjuvant systemic chemotherapy improves survival but more effective therapies are necessary.
- The immune system's role in cancer recognition and destruction offers potential for novel therapies.
Purpose of the Study:
- To explore the potential of immunotherapy as an adjuvant therapy for colorectal cancer.
- To highlight the cellular immune response as a principal anti-tumor mechanism.
- To discuss the development of colorectal cancer vaccines based on tumor-associated antigens.
Main Methods:
- Review of evidence for immune system recognition and destruction of malignant cells.
- Analysis of T cells recognizing tumors to identify colorectal tumor-associated antigens.
- Examination of current vaccine development strategies utilizing tumor-associated antigens.
Main Results:
- The cellular immune response, particularly T-cell mediated cytotoxicity, is a key anti-tumor mechanism.
- Numerous tumor-associated antigens, including specific colorectal antigens, have been identified.
- Understanding these antigens is crucial for developing effective cellular immune responses.
Conclusions:
- Immunotherapy holds significant promise for adjuvant treatment of colorectal cancer.
- Targeting tumor-associated antigens can facilitate the development of effective anti-cancer vaccines.
- Further research into cellular immune responses is vital for advancing colorectal cancer therapy.